Ligand Pharmaceuticals reported positive top-line results from its pivotal Phase 3 trial of a lead drug candidate for a rare metabolic disorder. The study met its primary and key secondary endpoints, with statistically significant and clinically relevant results.
The findings mark a step toward a potential New Drug Application (NDA) submission to the FDA. Company management said the results could support a new treatment option for patients.
Ligand shares moved higher in pre-market trading. The company plans to present the full data at an upcoming medical conference.